Multi-Site Concordance of Diffusion-Weighted Imaging Quantification for Assessing Prostate Cancer Aggressiveness
Overview
Authors
Affiliations
Background: Diffusion-weighted imaging (DWI) is commonly used to detect prostate cancer, and a major clinical challenge is differentiating aggressive from indolent disease.
Purpose: To compare 14 site-specific parametric fitting implementations applied to the same dataset of whole-mount pathologically validated DWI to test the hypothesis that cancer differentiation varies with different fitting algorithms.
Study Type: Prospective.
Population: Thirty-three patients prospectively imaged prior to prostatectomy.
Field Strength/sequence: 3 T, field-of-view optimized and constrained undistorted single-shot DWI sequence.
Assessment: Datasets, including a noise-free digital reference object (DRO), were distributed to the 14 teams, where locally implemented DWI parameter maps were calculated, including mono-exponential apparent diffusion coefficient (MEADC), kurtosis (K), diffusion kurtosis (DK), bi-exponential diffusion (BID), pseudo-diffusion (BID*), and perfusion fraction (F). The resulting parametric maps were centrally analyzed, where differentiation of benign from cancerous tissue was compared between DWI parameters and the fitting algorithms with a receiver operating characteristic area under the curve (ROC AUC).
Statistical Test: Levene's test, P < 0.05 corrected for multiple comparisons was considered statistically significant.
Results: The DRO results indicated minimal discordance between sites. Comparison across sites indicated that K, DK, and MEADC had significantly higher prostate cancer detection capability (AUC range = 0.72-0.76, 0.76-0.81, and 0.76-0.80 respectively) as compared to bi-exponential parameters (BID, BID*, F) which had lower AUC and greater between site variation (AUC range = 0.53-0.80, 0.51-0.81, and 0.52-0.80 respectively). Post-processing parameters also affected the resulting AUC, moving from, for example, 0.75 to 0.87 for MEADC varying cluster size.
Data Conclusion: We found that conventional diffusion models had consistent performance at differentiating prostate cancer from benign tissue. Our results also indicated that post-processing decisions on DWI data can affect sensitivity and specificity when applied to radiological-pathological studies in prostate cancer.
Level Of Evidence: 1 TECHNICAL EFFICACY: Stage 3.
Duenweg S, Bobholz S, Lowman A, Winiarz A, Nath B, Barrett M Front Oncol. 2025; 15:1433444.
PMID: 39990680 PMC: 11842255. DOI: 10.3389/fonc.2025.1433444.
LoCastro E, Paudyal R, Konar A, LaViolette P, Akin O, Hatzoglou V Tomography. 2023; 9(6):2052-2066.
PMID: 37987347 PMC: 10661267. DOI: 10.3390/tomography9060161.
Duenweg S, Bobholz S, Barrett M, Lowman A, Winiarz A, Nath B Cancers (Basel). 2023; 15(18).
PMID: 37760407 PMC: 10526331. DOI: 10.3390/cancers15184437.
Lawrence E, Zhang Y, Starekova J, Wang Z, Pirasteh A, Wells S Magn Reson Imaging. 2022; 93:108-114.
PMID: 35944809 PMC: 9523455. DOI: 10.1016/j.mri.2022.08.008.
Emerging MR methods for improved diagnosis of prostate cancer by multiparametric MRI.
Dwivedi D, Jagannathan N MAGMA. 2022; 35(4):587-608.
PMID: 35867236 DOI: 10.1007/s10334-022-01031-5.